Substitute for form 1449/PTO					Complete if Known				
				App	plication Number	10/6	552,814		
PENI	FORMA	ATION DISCLO ENT BY APPLIC	SURE	Filing Date August 29, 2003			gust 29, 2003		
) <u> </u>	TEM.	ENT BY APPLIC	CANT	Firs	st Named Inventor	Ung	ger		
APR 21 2006	(Use as	many sheets as necessary	יי	Art	Unit	163	6		
A	¥/			Exa	aminer Name	Rig	gins, P.	—	
Ramoout .	1	of	2		orney Docket Number		3.01US03		
O BOO	1 1	101			OCUMENTS			+	
			U.S. PATEN	I L		1	N of Patrick and A	{	
EXAMINER INITIAL	Cite No. ¹	Docume	nt Number		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	'	
		Number-Kin	d Code ^{2 (if known)}	\dashv				l	
IP		US-5,492,814			02-20-1996		Weissleder		
IP		US-6,255,457			07-03-2001		Schnitzer		
		US-		_					
		US-		\perp					
		US-							
	US-								
		US-		_					
		US-							
		US-							
		US-		_				<u>-</u> -	
		US-							
		US-							
		US-							
		US-		_					
		US-							
		US-							
		US-							
				TEN.	IT DOCUMENTS) 			
EXAMINER INITIAL	Cite No.1		tent Document		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	76	
		(if)	Number ⁴ Kind Code ⁵ known)						
IP		WO 99/29349			06-17-1999		Behr et al.	 	
					·				
			:						
EXAMINER	EXAMINER /Ileana Popa/				DATE		06/02/2006	L	
SIGNATURE		, 1100			CONSIDERED		n if not in conformance and not considered. Inc	lude	

copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation

		·								
Substitute for form 1449/PTO				Complete if Known						
				Application Number	10/652,814					
		ATION DISCLO		Filing Date	August 29, 2003					
ST		ENT BY APPLI		First Named Inventor	Unger					
	(Use a	s many sheets as necessa	יאין. יי	Art Unit	1636					
				Examiner Name	Riggins, P.					
Sheet	2	of	2	Attorney Docket Number	3193.01US03	, ,,,,, ,,,,,,				
		NON	N PATENT LITE	ERATURE DOCUME	ENTS					
EXAMINER INITIAL	Cite No.1	Include name of t item (book, maga	zine, journal, serial, sy	L LETTERS), title of the art imposium, catalog, etc.), date tity and/or country where pub	icle (when appropriate), title of the c, page(s), volume-issue number(s), plished	T²				
IP		225 (1998).			nn. Rev. Biochem., 67:199-					
IP		FENG ET AL Permeability to and Serotonin"	FENG ET AL., "Vesiculo-Vacuolar Organelles and the Regulation of Venule Permeability to Macromolecules by Vascular Permeability Factor, Histamine, and Serotonin", J. Exp. Med., 183:1981-1986 (1996).							
IP		VARGA ET Insights from	VARGA ET AL., "Receptor-mediated Targeting of Gene Delivery Vectors; Insights from Molecular Mechanisms for Improved Vehicle Design", Biotechnology and Bioengineering, 70(6): 593-605 (2000).							
			· · · · · · · · · · · · · · · · · · ·							
EXAMINER SIGNATURE		/I:	leana Popa/	DATE CONSIDERED	06/02/200	6				

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Complete if Known Substitute for form 1449/PTO 10/652.814 **Application Number** Filing Date August 29, 2003 INFORMATION DISCLOSURE TATEMENT BY APPLICANT First Named Inventor Unger (Use as many sheets as necessary) 1636 Art Unit Unknown **Examiner Name** 3193.01US03 Attorney Docket Number of NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the **EXAMINER** Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 INITIAL publisher, city and/or country where published AL-MOUSA, ET. AL, (1999) J Pharm Pharmacol 51(supplement):178, ΙP "Evidence for the role of caveolae in gene delivery." LEWIN ET. AL, (2000) Nature 18:410-414, "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells." ΙP MATVEEV ET. AL, (2001) Adv Drug Deliv Rev 49:237-250,"The role of ΤP caveolae and caveolin in vesicle-dependent and vesicle-independent trafficking." WOLFF ET. AL, (1992) J Cell Sci 103:1249-59, "Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of IP mammalian skeletal muscle."

SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

/Ileana Popa/

EXAMINER

DATE

CONSIDERED

06/02/2006

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

EXAMINER

Complete if Known							
Application Number	10/652,814						
Filing Date	August 29, 2003						
First Named Inventor	Unger						
Art Unit	1636						
Examiner Name	Unknown						

	(Use as many sneets as necessary)		Ar	Art Unit		1636		
PACTICAL PROPERTY.			Ex	xaminer Name		Unknown		
Sheet	1	of 8 /		At	Attorney Docket Number 3193.01US03			
	<u> </u>		U.S. PATE	NT I	DOCUMENTS	<u> </u>		
EXAMINER INITIAL*	EXAMINER Cite		nt Number		Publication Date MM-DD-YYYY		Name of Patentee or Applican of Cited Document	
IP		US-4,107,288			08-15-1978		Oppenheim et al.	
1		US-4,177,177			12-04-1979		Vanderhoff et al.	
		US-4,913,908			04-03-1990	-	Couvreur et al.	
		US-4,920,016			04-24-1990		Allen et al.	
		US-4,937,119			06-26-1990		Nikles et al.	
		US-4,968,350			11-06-1990		Bindschaedler et al.	
		US-5,116,507			05-14-1996		N'Guyen et al.	
		US-5,133,908 US-5,145,684 US-5,384,133 US-5,439,686		07-28-1992		Stainmesse et al.		
					09-08-1992		Liversidge et al.	
					01-24-1995		Boyes et al. Desai et al.	
					08-08-1995			
		US-5,498,421			03-12-1996		Grinstaff et al.	
		US-5,503,851			04-02-1996		Mank et al.	
		US-5,578,709			11-26-1996		Woiszwillo	
		US-5,629,021			05-13-1997		Wright	
		US-5,639,473			06-17-1997		Grinstaff et al.	
		US-5,639,480			06-17-1997	Bodmer et al.		
TP		US-5,648,095			07-15-1997	Illum et al.		
			FOREIGN PA	TEN	NT DOCUMENTS	3		
EXAMINER INITIAL*	Cite No.1	Foreign Patent Document		,	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Te
			known)					
IP		EP0860167			08-26-1998		Gurny	
IP		WO00/47130			08-17-2000		Devore	L
IP		WO88/08011			10-20-1988		Bindschaedler et al.	<u> </u>
IP		WO97/03702			02-06-1997		Mathiowitz et al.	

CONSIDERED SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include

/Ileana Popa/

DATE

06/02/2006

tanguage, translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Converce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language, Translation is attached.

Complete if Known Substitute for form 1449/PTO Application Number 10/652,814 Filing Date August 29, 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Unger (Use as many sheets as necessary) Art Unit 1636 **Examiner Name** Unknown 3193.01US03 Attorney Docket Number 2 of 8 Sheet U.S. PATENT DOCUMENTS **EXAMINER Publication Date** Name of Patentee or Applicant Cite Document Number MM-DD-YYYY of Cited Document INITIAL* No.1 Number-Kind Code2 (if known) 07-15-1997 Nuwayser IP US-5,648,097 US-5,736,156 07-07-1998 Burke US-5,759,582 06-02-1998 Leong et al. Margalit 12-08-1998 US-5,846,561 01-12-1999 Cho US-5,858,398 02-23-1999 Maitra et al. US-5,874,111 US-5,916,803 06-29-1999 Sedlacek et al. 10-05-1999 Goldstein et al. US-5,962,427 10-05-1999 Grandfils et al. US-5,962,566 US-5,985,832 11-16-1999 Roodman et al. 11-23-1999 Szoka Jr. et al. US-5,990,089 US-6.033.645 03-07-2000 Unger 04-18-2000 Kantor US-6,051,258 US-6,136,295 10-24-2000 Edwards et al. Verrecchia 10-31-2000 US-6,139,870 Goldstein et al. 11-07-2000 US-6,143,037 11-07-2000 Mathiowitz et al. US-6,143,211 Bissery et al. 11-14-2000 US-6,146,663 12-26-2000 Esenaliev US-6,165,440 TD FOREIGN PATENT DOCUMENTS **Publication Date** Foreign Patent Document **EXAMINER** Cite T⁶ MM-DD-YYYY Name of Patentee or Applicant INITIAL* No.1 of Cited Document Country Code³ Number⁴Kind Code³ (if known) 10-08-1998 WO98/43664 Kim et al. ΙP 01-07-1999 Desai et al. WO99/00113 IP WO99/33558 07-08-1999 Ouintanar-Guerrero et al. IP **EXAMINER** DATE /Ileana Popa/ 06/02/2006 **SIGNATURE** CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Complete if Known Substitute for form 1449/PTO 10/652,814 Application Number August 29, 2003 Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Unger (Use as many sheets as necessary) 1636 Art Unit Unknown **Examiner Name** Attorney Docket Number 3193.01US03 8 3 of Sheet U.S. PATENT DOCUMENTS Name of Patentee or Applicant **Publication Date EXAMINER** Cite of Cited Document MM-DD-YYYY INITIAL' No.1 Document Number Number-Kind Code2 (if known) 12-26-2000 Noe et al. US-6,165,988 IP Pace et al. US-6,177,103 01-23-2001 IP Mathiowitz et al. 03-06-2001 US-6,197,346 IP. 11-27-2001 Kim et al. US-6,322,805 ΙP 11-27-2001 Kim et al. US-6,322,805 ΙP 04-16-2002 Tanaka et al. ΙP US-6,372,714 10-14-2003 Unger US-6,632,671 IP US-US-US-US-US-US-US-US-US-US-US-US-FOREIGN PATENT DOCUMENTS **Publication Date** Foreign Patent Document EXAMINER Cite Τ⁶ Name of Patentee or Applicant MM-DD-YYYY INITIAL No. of Cited Document Country Code³ Number⁴Kind Code⁵ (if known) DATE 06/02/2006 **EXAMINER** /Ileana Popa/ **CONSIDERED SIGNATURE**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include convert this form with next communication to applicant.

copy of this form with next consummication to applicant.

'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 'For Japanese patent documents, the indication of the year of the reign of the Enteror must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO					Complete if Known					
			•		Application	on Number	10/652,814			
INFORMATION DISCLOSURE					Filing Da	te	August 29, 2003			
S			Y APPLICA	NT	First Nam	ned Inventor	Unger			
	(Ose	as many sne	eis as necessary)		Art Unit		1636	· · · · · ·		
					Examiner	Name	Unknown			
Sheet	4		of	8	Attorney	Docket Number	3193.01US03			
	. ;		NON P.	ATENT LITE	RATUR	RE DOCUME	NTS			
EXAMINER INITIAL	Cite No.1	Inclu item	ide name of the a	uthor (in CAPITA	AL LETTERS), title of the article (when appropriate), title of the ymposium, catalog, etc.), date, page(s), volume-issue number(s), city and/or country where published				Ţ [,] 2	
IP		Drug	AKHTAR, ET AL., (2000): The delivery of antisense therapeutics. Advanced Drug Delivery Reviews (44): 3-21.							
		(1993	ASH, ET AL., Handbook of Industrial Surfactants, Gower Publishing Co. (1993), pp. 885-905.							
		BAL	BALLY ET AL., (1999): Biological barriers to cellular delivery of lipid-based							
		DNA carriers, Advanced Drug Delivery Reviews (38):291-315.							ļ	
			BARRY, B. W., Dermatological Formulations: Percutaneous Absorption, pages 127-531.							
				(2000): Tran	sdermal	delivery of an	tisense comp	ounds.		
		Adva	nced Drug D	elivery Revie	ews (44)	51-57.				
				PAS (1997): aterials Maga		s in Controlle	d Drug Deliv	ery. Medical	:	
	-	BRO	NAUGH ET	AL Editors	Percuta	neous Absorp	tion Drugs-C	Cosmetics-		
		Mech	nanisms-Metl	hodology, 3rd	l Ed., (19	99), pp. 177-1	193; 597-613	and 879-886.		
		CAL	VO, ET AL.,	Comparitive	in vitro	Evaluation of	Several Coll	oidal Systems,		
		Nano	particles, Na	nocapsules, a	ind Nano	emulstions, a	s Ocular Drug	g Carriers,		
		Journ	nal of Pharma	aceutical Scie	nces, (19	95), pp. 530-	536.		<u> </u>	
		CAL	VO, ET AL,	Evaluation of	f Cationi	c Polymer-Co	ated Nanoca	psules as		
		Ocul	ar Drug Carr	iers, Internation	onal Jou	ral of Pharmac	microsphere), pp. 41-30.		
			DAMAGE ET AL., Intestinal Absorption of PLAGA microspheres in the rat, (1996) J. Anat, pp. 491-501.							
	_	DEAN, Lange's Handbook of Chemistry, 15th Edition, pages 1.74-1.343, 10.69-								
	10.73.								ļ	
		DOK	KA ET AL.,	(2000): Nov	el non-e	ndocytic deliv	very of antise	nse		
IP		oligo				very Reviews ((44): 33-49. T			
EXAMINER SIGNATUR		/Ileana Popa/ DATE CONSIDERED 06/02/2006								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

SIGNATURE

S	ubstitu	te for form 1449/P'	ГО	Complete if Known					
				Application Number		10/652,814			
		ATION DISCLOS		Filing Date		August 29, 2003			
ST		ENT BY APPLICATION Sheets as necessary)	ANT	First Named Invento	ог	Unger			
	(Ose as	muny sneets as necessaryy		Art Unit		1636			
				Examiner Name		Unknown			
Sheet	5	of	8	Attorney Docket Nu	ımber	3193.01US03			
		NON F	PATENT LITE	RATURE DOC	UMEN	NTS			
EXAMINER INITIAL	Cite No. ¹	Include name of the item (book, magazin	e, journal, serial, sy	L LETTERS), title of mposium, catalog, etc city and/or country wh	c.), date,	le (when appropriate), title of the page(s), volume-issue number(s), ished	T ²		
IP	GAUR ET AL., (2000): Biodistribution of fluoresceinated dextran using no nanoparticles evading reticuloendothelial system, International Journal of Pharmaceutics (2002):1-10.								
		Lippincott Willia	ms & Wilkins	, pp. 288-334; 72	21-752	Pharmacy, 20th Ed., ; 836-857 and 903-929.			
		GERNER ET AL., (1998): Similarity Between Nuclear Matrix Proteins of Various Cells Revealed by an Improved Isolation Method. Journal of Cellular Biochemistry (71) 363-374.							
		(38): 14069-1407	76.			ondensation. Biochemistry			
		Applications, Eu	r. J. Pharm. Bi	ophar. 42(1):1-1	1.	sion: Mechanisms and			
		JANES, ET AL., Macromolecules,	Polysaccharid Advanced Dr	le Colloidal Parti ug Delivery Rev	icles as	s Delivery Systems for 2001), pp. 83-97.			
		KATOAKA, ET AL., Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance, Advanced Drug Delviery Reviews (2001), pp. 113-131.							
		KAWASHIMA,	Nanoparticle S		roved I	Orug Delivery, Advanced			
		Drug Delivery Reviews (2001), pp. 1-2. KIBBE, ARTHUR H. EDITOR, (1986): Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Third Edition, pages 94-95, 117-120.							
		KREUTER, Mini-review: Nanoparticles and Microparticles for Drug and Vaccine Delivery, J. Anat. (1996), pp. 503-505.							
		GOLAN ET AL. (38): 14069-1407	, (1999): DNA 76.	Toroids: Stage	s in Co	ondensation. Biochemistry			
IP	GOPFERICH, (1995): Polymer Degradation and Erosion: Mechanisms and								
EXAMINER /Ileana Popa/ DATE CONSIDERED 06/02/2006									

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known						
					Applicati	on Number	10/652,814		
					Filing Da	ite	August 29, 2003		
ST.			BY APPLICA	NT	First Nan	ned Inventor	Unger		
	(Use as	many sne	eets as necessary)		Art Unit		1636		
					Examine	r Name	Unknown		
Sheet	6		of	8	Attomey	Docket Number	3193.01US03		
	<u> </u>		NON P	ATENT LITE	RATUI	RE DOCUME	NTS		
EXAMINER	Cite	Inch					icle (when appropriate), title of the	T ²	
INITIAL*	No.1								
		JANI	ES, ET AL.,	Polysaccharid	e Colloi	dal Particles a	as Delivery Systems for		
IP			•	•			(2001), pp. 83-97.		
		KAT	OAKA, ET	AL., Block Co	polyme	r Micelles for	Drug Delivery: Design,		
		Chara	acterization a	and Biological	Signific	cance, Advanc	ced Drug Delviery Reviews		
		(2001	1), pp. 113-1	31.					
		KAW	VASHIMA, I	Vanoparticle S	Systems	for Improved	Drug Delivery, Advanced		
		Drug	Delivery Re	views (2001),	pp. 1-2.	•			
		KIBE	BE, ARTHU	R H. EDITOR	, (1986)	: Handbook	of Pharmaceutical		
		Excip	pients, Amer	ican Pharmac	eutical A	Association, T	hird Edition, pages 94-95,		
		117-							
							particles for Drug and		
				, J. Anat. (199					
		L	•	•			very of Drugs, Advanced		
				views (2001),					
							ons, Microcapsules and		
		Nanc	particles in	Medicine and	Pharma	cy, pp. 125-14	1 50 4 11-1		
					d Drug I	Delivery Syste	ems, Journal of Controlled		
		Relea	ase (19914),	pp. 169-176.		01.41.1.1.	and Discostin	 	
		LAM	IAZE, ET A.	L., The Emerg	gence of	Clathrin-Inde	pendnet Pinocytic		
		Pathy	ways, Curren	t Opinion in (ell Bloi	ogy (1993), p	and shallenges. Gene	-	
					ene inera	py: promises	and challenges, Gene		
		Iner	apy (7): 31-3	4. (1006):	Dharma	ceutical Doca	ge Forms: Disperse		
	LIBERMAN, ET AL., (1996): Pharmaceutical Dosage Forms: Disperse Systems, Vol. 2, Second Edition, pages 1-109.								
I		Jrot	EDITOR	N CHIEF CI	C Hand	thook of Cher	nistry and Physics: A		
		Dogs	t, Dull UK I	Rook of Che	mical an	d Physical Da	ita, Chemical Rubber		
IP		Duki	ighing Co. 2	let (1922) no	7-7 to	7-9· 16-10 to	16-11; 16-43 to 16-47;		
			endix.	ιοι, (1722), μρ	. , , 10	. ,	,,		
EXAMINER		Tippe	/Ileana	Popa/		DATE	06/02/2006		
SIGNATURE	/11cana 10pa/								

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known				
			ł	Application Number	10/652,814		
INFORMATION DISCLOSURE			Filing Date	August 29, 2003			
ST		ENT BY APPLIC		First Named Inventor	Unger		
	(Use ns	many sheets as necessary)	, 	Art Unit	1636	· · · · · · · · · · · · · · · · · · ·	
			İ	Examiner Name	Unknown		
Sheet	7	of	8	Attorney Docket Number	3193.01US03		
		NON	PATENT LITE	ERATURE DOCUM	ENTS		
EXAMINER	Cite	Include name of the	author (in CAPITA	L LETTERS), title of the	article (when appropriate), title o	of the T ²	
INITIAL*	No.	item (book, magazir	ne, journal, serial, sy	ymposium, catalog, etc.), di city and/or country where p	ate, page(s), volume-issue numb	er(s),	
IP		MODLIN, (2000): A toll fro D	NA vaccines. Natur	e (408): 659-660.		
**		MULLER ET A	L., Nanosuspen	isions as Particulae l	Orug Formulations in		
					Can Expect for the Futur	re,	
				ews (2001), pp. 3-19			
		NISHIOKA FT	AL., Lymphatic	c Targeting with Na	noparticulate System,		
				ews (2001), pp. 55-6			
		NOONBERG F	T AL (1993):	Characteristics of (Oligonucleotide Uptake	in	
		Human Keratino	cyte Cultures	The Jouranal of Inv	enstigative Dermatology	y	
		(101): 727-731.	J - 2	32	_ 0.		
			l Engineers' Ha	ndbook, (1934), 7th	Ed. pp. 2-24 to 2-47.		
	<u> </u>				noparticles (SLN) for or	al	
		administration o	f Drugs, Pharm	nazie (1999), pp. 506	5-509.		
		QUINTANAR-(GUERRERO E	T AL., (1998): Prep	paration Techniques and		
,	[Mechanisms of	Formation of B	iodegradable Nanop	articles from Performed	l	
		Polymers. Drug	Development	and Industrial Pharn	nacy, 24(12): 1113-1128	3.	
		ROLLAND, (19	98): From Ger	nes to Gene Medicin	es: Recent Advances in)	
				cal Reviews in Tsher	rapeutic Drug Carrier		
	L	Systems 15(2):1	43-198.				
		SAKUMA ET A	L., Design of	Nanoparticles Comp	osed of Graft Copolyme	ers for	
		Oral Peptide De	livery, Advance	ed Drug Delivery Re	eviews (2001), pp. 21-37	7.	
		SCHMIDT, ET	AL., Incorpora	tion of Polymeric N	anoparticles into Solid		
		Dosage Forms, .	Iournal of Cont	trolled Release (199	7), pp. 115-125.		
					Reagents For Life Science	ce	
		Research, St. Lo	uis, MO. p 191	18.			
IP		SMITH, ET AL	Percutaneous		ers, (1995), pp. 1-20.		
EXAMINER		/11	.eana Popa/	DATE CONSIDERE	06/02	2/2006	

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known						
				Application Number	10/652,814					
		ATION DISCLOSU		Filing Date	August 29, 2003					
ST		ENT BY APPLICA many sheets as necessary)	ANT	First Named Inventor	Unger					
	(Use as	many sneets as necessary)		Art Unit	1636					
				Examiner Name	Unknown					
Sheet	8	of	8	Attorney Docket Number	3193.01US03					
		NON P	ATENT LITE	ERATURE DOCUM	ENTS					
EXAMINER INITIAL	Cite No.1	Include name of the a item (book, magazine	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
IP		Delivery, Advance	ed Drug Deliv	very Reviews (2001)	Systems for Peptide Drug , pp. 39-54.					
IP		New Courses, Ger	VILE, ET AL., Millenium Review: Cancer Gene Therapy: Hard Lessons and New Courses, Gene Therapy, pp. 2-8.							
IP		of Sterically Stabi Cancer Research	YUAN ET AL., (1994): Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (stealth) Liposomes in a Human Tumor Xenograft. Cancer Research (54) 3352-3356. ZHANG ET AL., (1997): Comparison of Integrins in Human Skin, Pig Skin, and Perfused Skin: An In Vitro Skin Toxicology Model. Journal of Appliced Toxicology 17(4): 247-253.							
IP -		and Perfused Skir								
EXAMINER SIGNATURE		/Ileana	Popa/	DATE CONSIDERE	D 06/02/2006					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.